Related references
Note: Only part of the references are listed.NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models
Chunxiao Xu et al.
TRANSLATIONAL ONCOLOGY (2022)
TGFβ-Directed Therapeutics: 2020
Beverly A. Teicher
PHARMACOLOGY & THERAPEUTICS (2021)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
Jitske van den Bulk et al.
CLINICAL SCIENCE (2021)
Randomized, Open-Label Study of Bintrafusp Alfa vs. Pembrolizumab as First-Line (1L) Treatment in Patients with PD-L1-Expressing Advanced Non-Small Cell Lung Cancer (NSCLC)
M. -J. Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Predicting immunotherapy response through genomics
Marina Candido Visontai Cormedi et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2021)
Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa
Ingrid Julienne Georgette Burvenich et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Davide Melisi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Brian T. Welsh et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2021)
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
Benjamin Tan et al.
TARGETED ONCOLOGY (2021)
Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials
J. Gulley et al.
ANNALS OF ONCOLOGY (2021)
Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.
Julius Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies.
Julius Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nabpaclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
Peter Grell et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, in patients with advanced solid tumors.
Dan Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.
Meiqi Shi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase Ib study of the anti-TGF-beta monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.
Todd Michael Bauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Elaine Chang et al.
ONCOLOGIST (2021)
A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys
Mayur S. Mitra et al.
TOXICOLOGICAL SCIENCES (2020)
Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
Constance J. Martin et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Christianne Groeneveldt et al.
TRENDS IN IMMUNOLOGY (2020)
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Simultaneous inhibition of CXCR1/2, TGF-beta, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
Lucas A. Horn et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Changhoon Yoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort
Toshihiko Doi et al.
ONCOLOGIST (2020)
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
Byoung Chul Cho et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Qingyang Lei et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
Julius Strauss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling
Warisara Parichatikanond et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2020)
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by -TGF antibody to promote durable rejection and immunity in squamous cell carcinomas
E. Dodagatta-Marri et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine Faivre et al.
LIVER INTERNATIONAL (2019)
Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Hendrik Ungefroren
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
Valeria Santini et al.
CLINICAL CANCER RESEARCH (2019)
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Xianguang Bai et al.
ONCOTARGETS AND THERAPY (2019)
Chimeric antigen receptors designed to overcome transforming growth factor-β-mediated repression in the adoptive T-cell therapy of solid tumors
Jordan Hartley et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2019)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3
Dorien Schepers et al.
HUMAN MUTATION (2018)
Immune checkpoint blockade combined with IL-6 and TGF- inhibition improves the therapeutic outcome of mRNA-based immunotherapy
Lukasz Bialkowski et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer
Alessandra Metelli et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Contextual determinants of TGFβ action in development, immunity and cancer
Charles J. David et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
625PDPembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study
M Ueno et al.
ANNALS OF ONCOLOGY (2018)
Transforming growth factor-β in stem cells and tissue homeostasis
Xin Xu et al.
BONE RESEARCH (2018)
TGF-beta downregulation-induced cancer cell death is finely regulated by the SAPK signaling cascade
Zhezhu Han et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Tumor-associated macrophages: from basic research to clinical application
Li Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
TGF-β, Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment
Michael W. Pickup et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2017)
The role of transforming growth factor (TGF)-β in the infarcted myocardium
Nikolaos G. Frangogiannis
JOURNAL OF THORACIC DISEASE (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
TGF-β-Induced Quiescence Mediates Chemoresistance of Tumor-Propagating Cells in Squamous Cell Carcinoma
Jessie A. Brown et al.
CELL STEM CELL (2017)
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Flavio Vincenti et al.
KIDNEY INTERNATIONAL REPORTS (2017)
Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin
Charlene Mantia et al.
BLOOD (2017)
Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms
Daniel Bedinger et al.
MABS (2016)
Phase II study of Vigil DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer
Jonathan Oh et al.
GYNECOLOGIC ONCOLOGY (2016)
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Alba A. Brandes et al.
NEURO-ONCOLOGY (2016)
The Discovery and Early Days of TGF-β: A Historical Perspective
Harold L. Moses et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins
Ian B. Robertson et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism
Michael Nabil Khoury et al.
NEURO-ONCOLOGY PRACTICE (2016)
Attenuation of the DNA Damage Response by Transforming Growth Factor-Beta Inhibitors Enhances Radiation Sensitivity of Non-Small-Cell Lung Cancer Cells In Vitro and In Vivo
Shisuo Du et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
Lisa M. Rice et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
The extracellular matrix and transforming growth factor-β1: Tale of a strained relationship
Boris Hinz
MATRIX BIOLOGY (2015)
Latent TGF-β-binding proteins
Ian B. Robertson et al.
MATRIX BIOLOGY (2015)
Transforming Growth Factor Beta Family: Insight into the Role of Growth Factors in Regulation of Fracture Healing Biology and Potential Clinical Applications
Lukasz A. Poniatowski et al.
MEDIATORS OF INFLAMMATION (2015)
TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis
Panagiotis Papageorgis
JOURNAL OF ONCOLOGY (2015)
First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
Jordi Rodon et al.
CLINICAL CANCER RESEARCH (2015)
TGFβ Receptor 1: An Immune Susceptibility Gene in HPV-Associated Cancer
Chaya Levovitz et al.
CANCER RESEARCH (2014)
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
John C. Morris et al.
PLOS ONE (2014)
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
Maria Gonzalez-Nunez et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
Expression of HPV16 E5 down-modulates the TGFbeta signaling pathway
Deborah French et al.
MOLECULAR CANCER (2013)
Resistance of Glioblastoma-Initiating Cells to Radiation Mediated by the Tumor Microenvironment Can Be Abolished by Inhibiting Transforming Growth Factor-β
Matthew E. Hardee et al.
CANCER RESEARCH (2012)
Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell Carcinoma
Stephen P. Malkoski et al.
CLINICAL CANCER RESEARCH (2012)
Matrix control of transforming growth factor-β function
Masahito Horiguchi et al.
JOURNAL OF BIOCHEMISTRY (2012)
Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties
Sergey V. Novitskiy et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
TGF-β - an excellent servant but a bad master
Lenka Kubiczkova et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm
Mark E. Lindsay et al.
NATURE GENETICS (2012)
TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy
Jeffrey P. Marcoe et al.
NATURE IMMUNOLOGY (2012)
TGFβ signalling in context
Joan Massague
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
TGF-β Sequestration by Mesangial Cell Integrin αvβ8 A Novel Mechanism of Glomerular Endothelial Cell Regulation
Ambra Pozzi et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Reduced SMAD7 Leads to Overactivation of TGF-β Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-β Receptor I Kinase
Li Zhou et al.
CANCER RESEARCH (2011)
TGFβ1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo
Fanny Bouquet et al.
CLINICAL CANCER RESEARCH (2011)
Latent TGF-β structure and activation
Minlong Shi et al.
NATURE (2011)
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Mark J. Anderton et al.
TOXICOLOGIC PATHOLOGY (2011)
Transient Tumor-Fibroblast Interactions Increase Tumor Cell Malignancy by a TGF-β Mediated Mechanism in a Mouse Xenograft Model of Breast Cancer
Christina H. Stuelten et al.
PLOS ONE (2010)
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Ethan M. Shevach
IMMUNITY (2009)
TGF-β Is Required for Vascular Barrier Function, Endothelial Survival and Homeostasis of the Adult Microvasculature
Tony E. Walshe et al.
PLOS ONE (2009)
Expression of GARP selectively identifies activated human FOXP3+regulatory T cells
Rui Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Transforming growth factor β1 promotes chromosomal instability in human papillomavirus 16 E6E7-infected cervical epithelial cells
Wen Deng et al.
CANCER RESEARCH (2008)
Matrix metalloproteinase 2 activation of transforming growth factor-β1 (TGF-β1) and TGF-β1-type II receptor signaling within the aged arterial wall
Mingyi Wang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
DA Thomas et al.
CANCER CELL (2005)
Transforming growth factor-β-related proteins:: an ancestral and widespread superfamily of cytokines in metazoans
A Herpin et al.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2004)
Making sense of latent TGFβ activation
JP Annes et al.
JOURNAL OF CELL SCIENCE (2003)
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
L Gorelik et al.
NATURE MEDICINE (2001)
Share Paper
